Company: INTS
Filing Date: 2025-04-25
Form Type: 8-K
Source: 0001628280-25-020057
Chunk: 0

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-04-25
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01. Entry into a Material Definitive Agreement

On April 24, 2025, Intensity Therapeutics, Inc., a Delaware corporation (the “ Company”), commenced a best efforts public offering (the “ Offering”) of an aggregate of (i) 3,133,333 shares (the “ Shares”) of the Company’s common stock, $0.0001 par value per share (the “ Common Stock”), (ii) 3,133,333 Series B-1 Common Warrants (the “ Series B-1 Common Warrants”) to purchase up to 3,133,333 shares of Common Stock (the “ Series B-1 Common Warrant Shares”), (iii) 3,133,333 Series B-2 Common Warrants (the “ Series B-2 Common Warrants” and together with the Series B-1 Warrants, the “ Warrants”) to purchase up to 3,133,333 shares of Common Stock (the “ Series B-2 Common Warrant Shares” and together with the Series B-1 Common Warrant Shares, the “ Warrant Shares”). Each Share was sold together with one Series B-1 Common Warrant to purchase one share of Common Stock and one Series B-2 Common Warrant to purchase one share of Common Stock. The combined offering price for each Share and accompanying Warrants was $0.75. Each Warrant will have an exercise price of $0.85 and be immediately exercisable. The Series B-1 Common Warrants will expire on the five-year anniversary of the date of issuance, and the Series B-2 Common Warrants will expire on the eighteen-month anniversary of the date of issuance.

The net proceeds of the Offering, after deducting the fees and expenses of the Placement Agents (as defined below), described in more detail below, and other offering expenses payable by the Company, but excluding the net proceeds, if any, from the exercise of the Warrants, are expected to be approximately $1.9 million. The Company intends to use the net proceeds from the Offering for the enrollment of patients in the INVINCIBLE-4 Study, for the treatment of existing patients enrolled in the INVINCIBLE-3 Study, and for working capital and general corporate purposes. The Company anticipates that the Offering will close on or about April 28, 2025, subject to the satisfaction of customary closing conditions.

In connection with the Offering, the Company entered into a Securities Purchase Agreement (the “ Purchase